Imjudo is expected to be introduced in Korea

Impinzi's combination therapy partner

AstraZeneca is in the process of licensing the Ministry of Food and Drug Safety

Among these, immuno-cancer treatments are the only approved first-line treatment for liver cancer

Another immuno-cancer drug with CTLA-4 inhibitory mechanism is expected to be introduced in Korea.

 

According to related industries, AstraZeneca Korea has submitted an application for domestic permission for CTLA-4 inhibitor Imjudo, a partner in combination therapy for PD-L1 inhibitor Impinzi.

 

The combination therapy of Impinzi and Imjudo was approved by the U.S.

 

FDA last month as an irreversible hepatocellular carcinoma treatment.

 

Combination therapy is the only dual immuno-cancer therapy allowed to date for the first round of liver cancer.

 

Combination therapy is a STRIDE (Single Tremelimumab Regular Interval Durvalumab) strategy in which Impinzi is additionally administered at regular intervals every 4 weeks after one dose of Impinzi 1500 mg and Imjudo 300 mg.

 

This combination therapy demonstrated OS benefits in phase 3 clinical HIMALAYA study, lowering the risk of death by 22% compared to the control Nexavar monotherapy.

 

The overall survival rate in the third year was 31% in the Impinzi and Imjudo combination therapy group and 20% in the Sorafenib monotherapy group.

 

Imjudo combination therapy recently added a lung cancer indication in the United States.

 

In phase 3 clinical POSEIDON study on which the permit was based, the patient group receiving a combination of Impinzi, Imjudo, and platinum-based chemotherapy showed a 23% lower risk of death compared to various chemotherapy controls.

 

The overall survival rate in the second year was 33% in the combined group and 22% in the control group.

 

Meanwhile, Imjudo is conducting a phase 3 study of combination therapy with Impinzi in several types of cancers, including local liver cancer (EMERALD-3 study), small cell lung cancer (ADRIATIC study), and bladder cancer (VOLGA and NILE study).